Search Results - "Carbajo, A Y"

Real-world use of mycophenolate mofetil in inflammatory bowel disease: Results from the ENEIDA registry by Hernández-Camba, A., Arranz, L., Vera, I., Carpio, D., Calafat, M., Lucendo, A.J., Taxonera, C., Marín, S., Garcia, M.J., Marín, G. Suris, Rodríguez, E. Sánchez, Carbajo, A.Y., De Castro, M.L., Iborra, M., Martin-Cardona, A., Rodríguez-Lago, I., Busquets, D., Bertoletti, F., Ausín, M. Sierra, Tardillo, C., Malaves, J. Huguet, Bujanda, L., Castaño, A., Domènech, E., Ramos, L., Merino, O.

“…Studies to evaluate the use of mycophenolate mofetil (MMF) in inflammatory bowel disease (IBD) are limited after the appearance of biological treatments. Our…”
Get full text

Effectiveness and Safety of the Switch from Remicade® to CT-P13 in Patients with Inflammatory Bowel Disease by Chaparro, M, Garre, A, Guerra Veloz, M F, Vázquez Morón, J M, De Castro, M L, Leo, E, Rodriguez, E, Carbajo, A Y, Riestra, S, Jiménez, I, Calvet, X, Bujanda, L, Rivero, M, Gomollón, F, Benítez, J M, Bermejo, F, Alcaide, N, Gutiérrez, A, Mañosa, M, Iborra, M, Lorente, R, Rojas-Feria, M, Barreiro-de Acosta, M, Kolle, L, Van Domselaar, M, Amo, V, Argüelles, F, Ramírez, E, Morell, A, Bernardo, D, Gisbert, J P

“…To evaluate the clinical outcomes in patients with IBD after switching from Remicade® to CT-P13 in comparison with patients who maintain Remicade®. Patients…”
Get full text

Real‐world short‐term effectiveness of ustekinumab in 305 patients with Crohn’s disease: results from the ENEIDA registry by Iborra, M., Beltrán, B., Fernández‐Clotet, A., Gutiérrez, A., Antolín, B., Huguet, J.M., De Francisco, R., Merino, O., Carpio, D., García‐López, S., Mesonero, F., Navarro, P., Ferreiro‐Iglesias, R., Carbajo, A.Y., Rivero, M., Gisbert, J.P., Piñero‐Pérez, M.C., Monfort, D., Bujanda, L., García‐Sepulcre, M.F., Martín‐Cardona, A., Cañete, F., Taxonera, C., Domènech, E., Nos, P., Sierra‐Ausín, M., Ferrer‐Rosique, J.A., Martín‐Arranz, M.D., González‐Muñoza, C., Manceñido, N., Rodriguez‐Lago, I., Benítez, J.M., Forés‐Bosch, A., Navarro‐Llavat, M., Calafat, M., Madrigal‐Domínguez, R.E., Arroyo, M., Busquets, D., Lorente, R., Sainz‐Arnau, E., Hernández‐Camba, A., Morales‐Alvarado, V.J., Paredes, J.M., Van Domselaar, M., Hervás, D., Cañada‐Martínez, A., Castro‐Poceiro, J., Cameo‐Lorenzo, J., Fernández‐Salazar, L., Riestra, S., Casas‐Deza, D., Tosca, J., Barrio, J., García, M.J., Chaparro, M.

“…Summary Background There are limited data of ustekinumab administered according to the doses recommended in the UNITI studies. Aim To assess the real‐world,…”
Get full text

P541 Diagnosis, management, and evolution of acute pancreatitis secondary to thiopurines in patients with Inflammatory Bowel Disease: an ENEIDA registry study by Guerra Marina, I, Barros, F, Mesonero, F, de Francisco, R, Cañete, F, Benítez, J M, Sicilia, B, Martín Arranz, M D, de Castro, L, Carbajo, A Y, Gutiérrez, A, Calvo, M, Casanova, M J, González-Muñoza, C, Miguel, M, Alfambra, E, Rivero, M, Lucendo, A J, Tardillo, C A, Almela, P, Bujanda, L, Van Domselaar, M, Ramos, L, Fernández Sánchez, M, Hinojosa, E, Verdejo, C, Gimenez, A, Piqueras, M, Rodríguez-Lago, I, Manceñido, N, Pérez Calle, J L, Moreno, M D P, Delgado, P G, Antolín, B, Ramírez de la Piscina, P, Bermejo, F, Carracedo, Á, Domènech, E, Gisbert, J P

“…Abstract Background Treatment with thiopurines in patients with Inflammatory Bowel Disease (IBD) may be associated with different adverse effects, including…”
Get full text

P905 Predictive pharmacogenetic risk of pancreatitis in Inflammatory Bowel Disease patients treated with thiopurines: a case-control study from the ENEIDA registry by Guerra Marina, I, Barros, F, Chaparro, M, Benítez, J M, Martín Arranz, M D, de Francisco, R, Piqueras, M, de Castro, L, Carbajo, A Y, Bermejo, F, Mínguez, M, Gutiérrez, A, Mesonero, F, Cañete, F, González-Muñoza, C, Calvo, M, Sicilia, B, Alfambra, E, Tardillo, C A, Rivero, M, Lucendo, A J, Bujanda, L, Van Domselaar, M, Almela, P, Ramos, L, Fernández Sánchez, M, Hinojosa, E, Verdejo, C, Gimenez, A, Rodríguez-Lago, I, Manceñido, N, Pérez Calle, J L, Moreno, M D P, Delgado-Guillena, P G, Antolín, B, Ramírez de la Piscina, P, Casanova, M J, Carracedo, Á, Domènech, E, Gisbert, J P

“…Abstract Background Treatment with thiopurines may be associated with different adverse effects, including acute pancreatitis. Risk factors for developing…”
Get full text

P476 Effectiveness and safety of ustekinumab in ulcerative colitis: Real-world evidence from the ENEIDA registry by Chaparro, M, Garre, A, Iborra, M, Sierra, M, Barreiro-de Acosta, M, Fernández-Clotet, A, de Castro, L, Boscá-Watts, M, Casanova, M J, López-García, A, Lorente, R, Rodríguez, C, Carbajo, A Y, Arroyo, M T, Gutiérrez, A, Hinojosa, J, Martínez-Pérez, T, Villoria, A, Bermejo, F, Busquets, D, Camps, B, Cañete, F, Manceñido, N, Monfort, D, Navarro-Llavat, M, Pérez-Calle, J L, Ramos, L, Rivero, M, Angueira, T, Camo, P, Carpio, D, García-de-la-Filia, I, González-Muñoza, C, Hernández, L, Huguet, J M, Morales, V J, Sicilia, B, Vega, P, Domènech, E, Gisbert, J P

“…Abstract Background The development program (UNIFI) has shown promising results of ustekinumab in ulcerative colitis (UC) treatment that should be confirmed in…”
Get full text

P584 Use of mycophenolate mofetil in inflammatory bowel disease: results from the ENEIDA registry by Hernandez Camba, A, Arranz, L, Vera, I, Carpio, D, Calafat Sard, M, Lucendo, A, Taxonera, C, Marín, S, Garcia, M J, Suris Marín, G, Sánchez Rodríguez, E, Carbajo, A Y, De Castro, M L, Iborra, M, Martin-Cardona, A, Rodríguez Lago, I, Busquets, D, Bertoletti, F, Sierra Ausín, M, Tardillo, C, Huguet Malaves, J, Bujanda, L, Castaño, A, Merino, O, Domènch, E, Ramos, L

“…Abstract Background Mycophenolate mofetil (MMF) is an immunomodulatory drug that inhibits T and B cells, through a reversible inhibition of inositol…”
Get full text

P434 Effectiveness and safety of ustekinumab in ulcerative colitis: real-world evidence from Eneida Registry by Chaparro, M, Garre, A, Iborra, M, Barreiro-de Acosta, M, Casanova, M J, De Castro, L, Fernández-Clotet, A, Hinojosa, J, Boscá-Watts, M, Busquets, D, López-García, A, Lorente, R, Manceñido, N, Martínez, T, Monfort, D, Pérez-Calle, J L, Villoria, A, Angueira, T, Bermejo, F, Carbajo, A Y, Carpio, D, González-Muñoza, C, Gomollón, F, Huguet, J M, Rivero, M, Iglesias-Flores, E, Sierra, M, Hernández-Villalba, L, Domènech, E, Gisbert, J P

“…Abstract Background Ustekinumab has shown promising results in ulcerative colitis (UC) in the development program (UNIFI) that should be confirmed in clinical…”
Get full text

P537 Real-world long-term effectiveness of ustekinumab in Crohn’s disease: Results from the ENEIDA registry by Iborra Colomino, M I, Beltrán, B, Fernández-Clotet, A, Iglesias Flores, E, Navarro, P, Rivero, M, Gutiérrez, A, Sierra-Ausin, M, Mesonero, F, Ferreiro-Iglesias, R, Hinojosa, J, Calvet, X, Sicilia, B, González-Muñoza, C, Antolín, B, González Vivo, M, Carbajo, A Y, García, S, Martín-Cardona, A, Surís Marín, G, Martín-Arranz, M D, De Francisco, R, Cañete, F, Carlos, T, Gomollón, F, Lorente, R, Rodríguez-Lago, I, Forés-Bosch, A, Bernardos, E, Ramos, L, Delgado, P, Hernández, A, Van Domselaar, M, Hervás, D, Domènech, E, Nos, P

“…Abstract Background There are limited data of long-term ustekinumab administered according to the doses recommended in the UNITI studies. The objective of this…”
Get full text

OP29 Tofacitinib in ulcerative colitis: Real-world evidence from Eneida Registry by Chaparro, M, Garre, A, Mesonero, F, Rodríguez, C, Barreiro-de Acosta, M, Martínez-Cadilla, J, Arroyo, M T, Manceñido, N, Sierra-Ausín, M, Vera-Mendoza, I, Casanova, M J, Nos, P, González-Muñoza, C, Martínez, T, Boscá-Watts, M, Busquets, D, Calafat, M, Girona, E, Llaó, J, Martín-Arranz, M D, Piqueras, M, Ramos, L, Suis, G, Bermejo, F, Carbajo, A Y, Casas-Deza, D, Fernández-Clotet, A, García, M J, Ginard, D, Gutiérrez-Casbas, A, Hernández-Villalba, L, Lucendo, A J, Márquez, L, Merino-Ochoa, O, Rancel, F J, Taxonera, C, López Sanromán, A, Rubio, S, Domènech, E, Gisbert, J P

“…Abstract Background Our aim was to evaluate the effectiveness and safety of tofacitinib in ulcerative colitis (UC) in real life. Methods Patients from the…”
Get full text

P505 Real-world short-term effectiveness of ustekinumab in Crohn’s disease: Results from the ENEIDA Registry by Iborra, M, Beltrán, B, Fernández, A, Gutiérrez, A, Antolín, B, Huguet, J M, de Francisco, R, Merino, O, Carpio, D, García López, S, Mesonero, F, Mínguez, M, Ferreiro, R, Carbajo, A Y, Rivero, M, Chaparro, M, Piñero-Pérez, M C, Monfort i Miquel, D, Bujanda, L, García-Sepulcre, M F, Martín-Cardona, A, Cañete, F, Taxonera, C, Sierra-Ausin, M, Ferrer-Rosique, J Á, Martín-Arranz, M D, González-Muñosa, C, Manceñido-Marcos, N, Rodríguez-Lago, I, Iglesias-Flores, E, Forés-Bosch, A, Navarro-Llavat, M, Calafat, M, Madrigal-Domínguez, R E, Ramos, L, Arroyo, M, Busquets, D, Lorente, R, Saiz-Arnau, E, Hernández-Camba, A, Jair-Morales, V, Paredes, C, Van Domselaar, M, Hervás, D, Cañada-Martínez, A, Nos, P

“…Abstract Background Ustekinumab is a monoclonal antibody targeting interleukins 12 and 23. Its effectiveness in clinical practice has not yet been…”
Get full text

P443 Clinical features, therapeutic requirements, and evolution of patients with Crohn's disease and upper digestive tract involvement (CROHNEX study) by Sainz Arnau, E, Zabana, Y, Miguel, I, Fernández Clotet, A, Casanova, M J, Martín, M D, Picó, M D, Alfambra, E, Rodriguez, I, Muñoz, F, Domínguez, M, Iglesias, E, Busquets, D, Gutiérrez, A, Cañete, F, Nuñez, L, Taxonera, C, Beltrán, B, Camps, B, Calvet, X, Navarro, P, Calafat, M, Ferreiro-Iglesias, R, González-Muñoza, C, Sicilia, B, Rodríguez, C, Carbajo, A Y, van Domselaar, M, Vicente, R, Piqueras, M, Muñoz, M C, Abad, À, Algaba, A, Martínez, P, Vela, M I, Antolín, B, Huguet, J M, Bujanda, L, Lorente, R H, Almela, P, García, M J, Ramírez de la Piscina, P, Pajares, R, Pérez-Martínez, I, Lucendo, A J, Merino, O, Legido, J, Vera, I, Morales, V J, Esteve, M

“…Abstract Background Patients with upper (L4) and diffuse (L1 + L4) Crohn's disease (CD) may have a more aggressive and refractory disease course. However,…”
Get full text

P275 Clinical characteristics, associated malignancies and management of primary sclerosing colangitis in inflammatory bowel disease patients: A Spanish nationwide study based on the ENEIDA registry by Guerra, I, Bujanda, L, Castro, J, Merino, O, Tosca, J, Camps, B, Gutiérrez, A, Gordillo, J, de Castro, L, Iborra, M, Carbajo, A Y, Taxonera, C, Rodriguez - Lago, I, Mesonero, F, de Francisco, R, Gómez-Gómez, G J, Chaparro, M, Tardillo, C A, Rivero, M, Algaba, A, Martín-Arranz, E, Cañete, F, Vicente, R, Sicilia, B, Antolín, B, Prieto, V, Márquez, L, Benítez, J M, Camo, P, Piqueras, M, Gargallo, C J, Hinojosa, E, Huguet, J M, Pérez Calle, J L, Van Domselaar, M, Rodriguez, C, Calvet, X, Muñoz, M C, García-Sepulcre, M F, Bermejo, F, Bañales, J M, Gisbert, J P

“…Abstract Background Primary sclerosing colangitis (PSC) is a chronic cholestasic liver disease usually associated with inflammatory bowel disease (IBD). An…”
Get full text

P391 The availability of anti-TNF agents is associated with reduced early surgical requirements in Crohn’s disease but not in ulcerative colitis. A nationwide study from the Eneida registry by Guasch, M, Clos, A, Ordás, I, García-Sánchez, V, Gisbert, J P, Taxonera, C, Vera, I, Mínguez, M, Guardiola, J, López-Sanromán, A, Rivero-Tirado, M, Nos, P, Gomollón, F, Carbajo, A Y, de Francisco, R, Martín-Arranz, M D, Garcia-Planella, E, García-López, S, de Castro, L, Calvet, X, Camargo, R, Esteve, M, Sicilia, B, Andreu, M, Macho, A, Piqueras, M, Bermejo, F, Gutiérrez, A, Busquets, D, Martínez-Montiel, P, Hinojosa, J, Pérez-Calle, J L, Bujanda, L, Rodríguez-Pérez, A, Lorente, R, Jiménez, N, Navarro-Llavat, M, Cabriada, J L, Camo, P, Van Domselaar, M, Rodríguez-González, E, Rodríguez-Gutiérrez, C, Huguet, J M, Lucendo, A J, Argüelles, F, Almela, P, Merino, O, Calafat, M, Ogueta, M, Charro, M, Llaó, J, Muñoz, C, Ramos, L, Abad, Á, Roncero, Ó, Barreiro-de-Acosta, M, Sesé, E, Mañosa, M, Domènech, E

“…Abstract Background It has been suggested that biological therapies might change the natural history of IBD, avoiding surgery in a proportion of patients…”
Get full text